Several observational studies of COVID-19 patients indicate famotidine, a selective H2R antagonist widely used to treat gastroesophageal reflux disease, improves survival in hospitalized patients and ameliorates symptoms in non-hospitalized patients (Janowitz et al. 2020; Freedberg et al. 2020) when administered at a high dose. The gene discussed is HRH2; the disease is gastroesophageal reflux disease.